Advanced Enzyme Tech Ltd
NSE: ADVENZYMES · Biotechnology · sector
₹252.15NSE close 2026-10-26
Key numbers
Market cap₹2,823 cr
Price₹252.15
52w high / low₹419 / ₹252
P/E17.0xSector median 40.2x
P/B1.7xSector median 1.4x
Book value₹145.7
Dividend yield2.11%Sector median 2.11%
ROE10.9%Sector median -0.0%
ROCE14.1%Sector median 3.3%
OPM31.3%Sector median 31.3%
Debt / equity0.01xSector median 0.01x
EV/EBITDA9.1xSector median 34.1x
Interest cover95.6x
Current ratio9.78x
Sales growth 3y+11.3%Sector median -26.4%
Profit growth 3y+16.9%Sector median -43.0%
PEG1.01x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 6 companies in Biotechnology (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹700 cr vs borrowings ₹21 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 95.6x in the last 12 months.
- No promoter shares are pledged.
- Operating cash flow was below net profit in 1 of the last 5 years (FY26).
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 24% of net profit in the last 12 months.
- Debtor days went from 58 (FY24) to 71 (FY26).
- Dividend paid in 5 of the last 5 financial years.
- Price ₹252.15 on 2026-10-26: -39.8% from the 52-week high, +0.1% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹517.30 · low ₹252.15
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 146 | 169 | 167 | 186 | 185 | 172 | 203 | 190 |
| EBITDA | 42 | 55 | 46 | 56 | 60 | 61 | 63 | 51 |
| OPM % | 29.0% | 32.7% | 27.3% | 30.4% | 32.5% | 35.2% | 31.1% | 26.9% |
| Other income | 10 | 8 | 9 | 9 | 10 | 8 | 7 | 13 |
| Net profit | 33 | 38 | 26 | 40 | 43 | 42 | 43 | 37 |
| EPS (₹) | 2.94 | 3.36 | 2.37 | 3.57 | 3.87 | 3.80 | 3.84 | 3.31 |
| Revenue YoY | +26.3% | +1.7% | +21.6% | +2.1% | ||||
| Profit YoY | +32.0% | +12.9% | +62.2% | -7.1% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 529 | 541 | 624 | 637 | 746 | 750 |
| EBITDA | 201 | 152 | 189 | 194 | 240 | 235 |
| Net profit | 120 | 106 | 133 | 131 | 169 | 166 |
| EPS (₹) | 10.70 | 9.45 | 11.92 | 11.72 | 15.08 | 14.82 |
| Revenue growth | +2.1% | +15.4% | +2.1% | +17.1% | +12.2% | |
| Profit growth | -11.7% | +26.2% | -1.6% | +28.7% | +21.2% | |
| Dividend / share (₹) | 0.90 | 1.00 | 5.00 | 5.10 | 5.20 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +11.3% | +8.2% | +12.2% |
| Net profit | +16.9% | +2.9% | +21.2% |
| EPS | +16.9% | +2.9% | – |
| Share price | – | -24.8% (2y) | -17.6% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 1,235 | 1,324 | 1,421 | 1,632 |
| Borrowings | – | 13 | 25 | 22 | 21 |
| Cash & equivalents | – | 483 | 546 | 588 | 700 |
| Total assets | – | 1,422 | 1,535 | 1,621 | 1,839 |
| Fixed assets | – | 273 | 277 | 293 | 276 |
| Capital work in progress | – | 16 | 31 | 22 | 51 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 100 | 99 | 115 | 145 |
| Inventory | – | 124 | 148 | 157 | 177 |
| Payables | – | 24 | 16 | 17 | 40 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 124 | 140 | 141 | 142 | 157 |
| Cash from investing | -26 | -298 | -65 | -89 | -74 |
| Cash from financing | -27 | -26 | -59 | -73 | -70 |
| Capex | 28 | 38 | 47 | 35 | 52 |
| Free cash flow | 95 | 102 | 94 | 108 | 104 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 8.6% | 10.1% | 9.2% | 10.3% |
| ROCE % | – | 11.4% | 14.1% | 13.2% | 14.2% |
| Debtor days | – | 68 | 58 | 66 | 71 |
| Inventory days | – | 343 | 375 | 378 | 335 |
| Payable days | – | 67 | 40 | 41 | 76 |
| Cash conversion cycle (days) | – | 344 | 393 | 403 | 330 |
| Working capital days | – | 435 | 412 | 449 | 459 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 43.56% |
| FIIs | 26.65% |
| DIIs | 1.89% |
| of which Mutual funds | 1.18% |
| Public (non-institutions) | 27.90% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 42.93% | 43.08% | 43.08% | 43.07% | 43.04% | 43.26% | 43.24% | 43.56% |
| Promoter group | % |
|---|---|
| Vasant Rathi | 26.87% |
| Vasant and Prabha Rathi Generation Trust | 6.75% |
| Rasika Vasant Rathi | 2.40% |
| Reshma Namita Rathi | 2.38% |
| Rachana Vasant Rathi | 2.38% |
| Kishor Laxminarayan Rathi HUF | 0.99% |
| Prabhavati Vasant Rathi | 0.82% |
| Madhusudan Kabra | 0.55% |
| Kishor Laxminarayan Rathi | 0.37% |
| Jayesh Madhusudan Soni | 0.01% |
| Megha Jhawar | 0.01% |
| Snehal Shamsunder Soni | 0.01% |
| Shruti Sharad Dhamdhere | 0.01% |
| Pratik Prakash Kokane | 0.01% |
| Savita Chandrakumar Rathi | 0.00% |
| Public holders above 1% | % |
|---|---|
| Orbimed Asia III Mauritius FVCI Limited | 12.15% |
| Nalanda India Equity Fund Limited | 8.38% |
| Polunin Emerging Markets Small Cap Fund, LLC | 2.48% |
| Marval Guru Fund | 1.80% |
| Pradip Bhailal Shah | 1.67% |
| Mukund Madhusudan Kabra | 1.64% |
67,468 shareholders. Pledged: 0.00% of promoter shares.
Peers in Biotechnology
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| ANTHEM | ₹46,324 cr | 80.2x | 15.2x | 18.9% | 25.5% | 38.4% | – | – |
| ADVENZYMES | ₹2,823 cr | 17.0x | 1.7x | 10.9% | 14.1% | 31.3% | +11.3% | 2.11% |
| CCME | ₹43 cr | 58.0x | 1.1x | -3.5% | -2.1% | – | – | – |
| VIVOBIOT | ₹29 cr | 3.6x | 0.3x | -3.3% | 5.8% | 37.0% | +1.1% | – |
| SHREEGANES | ₹18 cr | 22.5x | 0.3x | -0.6% | -0.6% | -35.1% | -57.0% | – |
| GVBL | ₹12 cr | 329.9x | 3.1x | 0.5% | 0.8% | 15.6% | -53.8% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-07-24 | Dividend | Dividend - Rs 1.35 Per Share |
| 2025-07-23 | Dividend | Dividend - Rs 1.20 Per Share |
| 2025-05-16 | Dividend | Interim Dividend - Rs 4 Per Share |
| 2024-07-18 | Dividend | Dividend - Re 1.1 Per Share |
| 2024-05-17 | Dividend | Interim Dividend - Rs 4 Per Share |
| 2023-08-04 | Dividend | Dividend - Re 1 Per Share |
| 2023-05-19 | Dividend | Interim Dividend - Rs 4 Per Share |
| 2022-08-11 | Dividend | Dividend - Re 1 Per Share |
| 2021-08-31 | Dividend | Dividend - Rs 0.90 Per Share |
| 2020-07-09 | Dividend | Annual General Meeting/Dividend - Rs 0.60 Per Share |
| 2019-08-01 | Dividend | Annual General Meeting/Dividend - Rs 0.60 Per Share |
| 2018-09-06 | Dividend | Annual General Meeting/Dividend Re 0.50 Per Share |
| 2017-09-04 | Dividend | Annual General Meeting/Dividend - Re 0.40 Per Share(Book Closure Dates Revised) |
| 2017-05-25 | Split | Face Value Split From Rs 10/- Per Share To Rs 2/- Per Share |
| 2016-09-08 | Other | Annual General Meeting |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Manufacturing: Chemical and chemical products; pharmaceuticals; medicinal chemical and botanical products
| Sector | Healthcare |
| Industry | Biotechnology |
| Sub-industry | Biotechnology |
| Symbol | ADVENZYMES |
| BSE code | 540025 |
| ISIN | INE837H01020 |
| Face value | ₹2.0 |
| Incorporated | 1989-03-15 |
| Website | www.advancedenzymes.com |
| Plants (India / abroad) | 4 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.